ELEVATE-TN Shows Acalabrutinib Is Well-Tolerated in CLL
Jeff P. Sharman, MD, discusses the safety profile of acalabrutinib that was demonstrated in the phase III ELEVATE-TN trial. The trial evaluated acalabrutinib as a single agent or in…
Related Articles
Treatment Options for Patients with Neuroendocrine Tumors
A panelist discusses how first-line treatment options for neuroendocrine tumors depend on tumor grade, disease extent, and symptoms, ranging from observation for asymptomatic cases to…
Barata and Participants Discuss Second- Line and Later Options in RCC
During a live event, Pedro C. Barata, MD, MSc, discussed the case of a patient with advanced clear cell renal cell carcinoma who requires second-line…
How Tariffs May Affect Oncology Professionals and Patients
Mack Roach III, MD, discusses concerns about how tariffs and restrictions on international collaboration could negatively affect cancer research and treatment.
Improving Prostate Cancer Screening With an AI Model
Madhur Nayan, MD, PhD, discusses a new machine learning model developed to enhance prostate cancer screening.
Belrestotug Program Terminated After Mixed Phase 2 Results in NSCLC
Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all development and ongoing trials.
Navigating the Transformation of AI Cancer Detection and Diagnosis
Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.
Current Evidence and Clinical Algorithms for Targeted Management of Polycythemia Vera: Applying Trial Insights to Patient Care
Panelists discuss how polycythemia vera treatment follows a risk-stratified approach, with all patients receiving daily aspirin and phlebotomies to maintain hematocrit below 45%, while high-risk…
Pragmatic AI and Strategic Planning for Community Oncology Practices
Nini Wu, MD, MBA, discusses the future of technology in community oncology, particularly highlighting the pervasive topic of artificial intelligence.
Pembrolizumab Improves PFS in Recurrent Ovarian Cancer
The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end point of progression-free survival.
Navigating the Challenges of Advanced Cancer Remission Testing
Dong Chen, MD, PhD, discusses the obstacles and opportunities for growth in posttreatment cancer detection.